Abstract 3312
Background
Salvage radiotherapy (SRT) is a potentially curative option for patients with rising PSA (biochemical recurrence) after radical prostatectomy. Recently, success rates of SRT were significantly improved through the use of concomitant anti-androgen (AAT) or androgen-deprivation (ADT) therapy. In RTOG 96-01, 2 years of bicalutamide 150 mg resulted in a 5% OS benefit at 12-years. In GETUG-AFU 16, 5-year progression-free survival was significantly improved when SRT was combined with 6 months of an LHRH agonist. Based on GETUG-AFU 16, most European urologists and (radiation) oncologists now combine SRT with at least 6 months of ADT. However, ADT comes with several serious side-effects, both physical (cardiovascular, metabolic, musculoskeletal) and psychological (sexual, emotional and cognitive). Considering RTOG 96-01, and in view of new AAT options, it appears worthwhile to look for alternatives. In that respect, apalutamide (ERLEADA®), a next-generation anti-androgen, is an interesting candidate.
Trial design
This is a phase II randomized, open-label study comparing SRT in combination with 6 months of LHRH (ant)agonist (arm A) versus 6 cycles of apalutamide 240 mg daily (each cycle is 28 +/- 2 days) (arm B) in hormone-naïve patients with biochemical recurrence (PSA > 0.1 µg/L at least 8 weeks after radical prostatectomy). Patients with severe erectile dysfunction are excluded. All subjects will receive SRT as standard of care and will be randomly assigned in a 1:1 ratio to arm A or B. Primary objective is to compare sexual function, based on the EPIC-26 sexual domain score, at 9 months (i.e. 3 months after the end of hormonal treatment). Secondary endpoints include general quality of life (EPIC-26, EORTC QLQ C30 and PR25, FACT-P), acute as well as late toxicity (CTCAE version 5.0), and PSA (complete) response rates (i.e. decline from baseline in PSA level of 80% (90%) or greater). The trial was approved by the local ethics committee on April 2nd 2019 and started recruiting immediately thereafter.
Clinical trial identification
NCT03899077; 2018-004365-13.
Editorial acknowledgement
Legal entity responsible for the study
GZA Hospitals.
Funding
Janssen.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5801 - Implementing a Population-Based Cancer Registries Network in Mexico
Presenter: Alejandra Palafox-Parrilla
Session: Poster Display session 3
Resources:
Abstract
4385 - Awareness of cancer risk factors among high school students
Presenter: Monika Rucinska
Session: Poster Display session 3
Resources:
Abstract
3355 - COMPRAYA: Dutch nationwide infrastructure for COMPRehensive health outcome and intervention research among patients with Adolescent and Young Adult cancer
Presenter: Olga Husson
Session: Poster Display session 3
Resources:
Abstract